Modality
Bispecific Ab
MOA
PCSK9i
Target
FcRn
Pathway
Apoptosis
Breast Ca
Development Pipeline
Preclinical
~Feb 2016
→ ~May 2017
Phase 1
~Aug 2017
→ ~Nov 2018
Phase 2
Feb 2019
→ Aug 2026
Phase 2Current
NCT06929826
1,751 pts·Breast Ca
2019-02→2026-08·Completed
NCT08220177
2,879 pts·Breast Ca
2023-12→TBD·Completed
4,630 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-08-225mo awayPh3 Readout· Breast Ca
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P2/3
Complet…
P2/3
Complet…
Catalysts
Ph3 Readout
2026-08-22 · 5mo away
Breast Ca
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06929826 | Phase 2/3 | Breast Ca | Completed | 1751 | EASI-75 |
| NCT08220177 | Phase 2/3 | Breast Ca | Completed | 2879 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| INC-1261 | Incyte | Phase 1/2 | PRMT5 |